PE20010989A1 - 8-ARYLQUINOLINES SUBSTITUTED INHIBITORS OF 4-PHOSPHODIESTERASE - Google Patents
8-ARYLQUINOLINES SUBSTITUTED INHIBITORS OF 4-PHOSPHODIESTERASEInfo
- Publication number
- PE20010989A1 PE20010989A1 PE2000001396A PE0013962000A PE20010989A1 PE 20010989 A1 PE20010989 A1 PE 20010989A1 PE 2000001396 A PE2000001396 A PE 2000001396A PE 0013962000 A PE0013962000 A PE 0013962000A PE 20010989 A1 PE20010989 A1 PE 20010989A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- halogen
- alkyl
- arylquinolines
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940124225 Adrenoreceptor agonist Drugs 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- -1 M2 / M3 ANTAGONIST Substances 0.000 abstract 1
- 229940126083 M3 antagonist Drugs 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- FSEXLNMNADBYJU-UHFFFAOYSA-N alpha-Phenylquinoline Natural products C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 102000003835 leukotriene receptors Human genes 0.000 abstract 1
- 108090000146 leukotriene receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A 8-ARILQUINOLINAS SUSTITUIDAS DE FORMULA I DONDE S1, S2, S3 SON H, CN, ALCOXI C1-C6, OH, HALOGENO, ENTRE OTROS; R1 ES H, OH, HALOGENO, CARBONILO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; A ES CH, C-ESTER, CR4; R2 Y R3 SON ARILO, HETEROARILO, H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R4 ES ARILO, ALQUILO C1-C6, HETEROARILO, CN, CARBONILO, ENTRE OTROS; R2 O R3 OPCIONALMENTE UNIDO A R4 POR UN ENLACE FORMAN UN ANILLO. SON COMPUESTOS PREFERIDOS 6-ISOPROPIL-8-(3-{(Z/E)-2-[4-(METILSULFONIL)FENIL]-2-FENILETENIL}FENILQUINOLINA, ENTRE OTROS; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS ANTAGONISTA DE RECEPTORES DE LEUCOTRIENO, INHIBIDOR DE LA BIOSINTESIS DE LEUCOTRIENO, ANTAGONISTA M2/M3, CORTICOSTEROIDE, UN ANTAGONISTA DE RECEPTORES H1, AGONISTA DE ADRENORECEPTORES ß2. EL COMPUESTO I ES UN INHIBIDOR DE FOSFODIESTERASA 4 PDE4 Y PUEDE SER UTIL PARA EL TRATAMIENTO DEL ASMA, BRONQUITIS CRONICA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, PSORIASISREFERS TO 8-ARYLQUINOLINES SUBSTITUTED FOR FORMULA I WHERE S1, S2, S3 ARE H, CN, C1-C6 ALCOXY, OH, HALOGEN, AMONG OTHERS; R1 IS H, OH, HALOGEN, CARBONYL, C1-C6 ALKYL, C3-C6 CYCLOALKYL, AMONG OTHERS; A IS CH, C-ESTER, CR4; R2 AND R3 ARE ARYL, HETEROARYL, H, HALOGEN, CN, C1-C6 ALKYL, AMONG OTHERS; R4 IS ARYL, C1-C6 ALKYL, HETEROARYL, CN, CARBONYL, AMONG OTHERS; R2 OR R3 OPTIONALLY JOINED TO R4 BY A LINK FORM A RING. PREFERRED COMPOUNDS ARE 6-ISOPROPIL-8- (3 - {(Z / E) -2- [4- (METHYLSULFONIL) PHENYL] -2-PHENYLETHENIL} PHENYLQUINOLINE, AMONG OTHERS; IT ALSO REFERS TO A COMPOSITION THAT ALSO INCLUDES ANTAGONISM LEUKOTRIENE RECEPTORS, LEUCOTRIENE BIOSYNTHESIS INHIBITOR, M2 / M3 ANTAGONIST, CORTICOSTEROID, AN H1 RECEPTOR ANTAGONIST, ß2 ADRENORECEPTOR AGONIST. COMPOUND I IS AN INHIBITOR OF FOSE-4 SERIES INHIBITOR PDOSAQUATFTILITER PDO4 AND UTILITY 4 INHIBITOR PDOSETISA CHRONIC, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, PSORIASIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17152299P | 1999-12-22 | 1999-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010989A1 true PE20010989A1 (en) | 2001-10-01 |
Family
ID=22624050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001396A PE20010989A1 (en) | 1999-12-22 | 2000-12-22 | 8-ARYLQUINOLINES SUBSTITUTED INHIBITORS OF 4-PHOSPHODIESTERASE |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1244628A1 (en) |
| JP (1) | JP3782011B2 (en) |
| KR (1) | KR20020082839A (en) |
| CN (1) | CN1221534C (en) |
| AR (1) | AR029214A1 (en) |
| AU (1) | AU778531B2 (en) |
| BG (1) | BG65403B1 (en) |
| BR (1) | BR0016651A (en) |
| CA (1) | CA2393749C (en) |
| CO (1) | CO5261613A1 (en) |
| CZ (1) | CZ20022171A3 (en) |
| DZ (1) | DZ3244A1 (en) |
| EA (1) | EA004747B1 (en) |
| EE (1) | EE200200342A (en) |
| GE (1) | GEP20053626B (en) |
| HR (1) | HRP20020545A2 (en) |
| HU (1) | HUP0203896A3 (en) |
| IL (1) | IL150114A0 (en) |
| IS (1) | IS6413A (en) |
| MX (1) | MXPA02006329A (en) |
| MY (1) | MY134008A (en) |
| NO (1) | NO20023013L (en) |
| NZ (1) | NZ520258A (en) |
| PE (1) | PE20010989A1 (en) |
| PL (1) | PL355752A1 (en) |
| SK (1) | SK8972002A3 (en) |
| TW (1) | TWI280240B (en) |
| UA (1) | UA74815C2 (en) |
| WO (1) | WO2001046151A1 (en) |
| YU (1) | YU47102A (en) |
| ZA (1) | ZA200204862B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10110772A1 (en) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and PDE-IV inhibitors |
| US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| DE60111648T2 (en) * | 2000-12-20 | 2006-05-11 | Merck & Co., Inc. | Process for the preparation of substituted 8-arylquinolinium benzenesulfonate |
| WO2003002118A1 (en) * | 2001-06-27 | 2003-01-09 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline pde4 inhibitors |
| US7009055B2 (en) * | 2001-07-24 | 2006-03-07 | Merck & Co., Inc. | Preparation of Sulfonyl quinoline |
| JP2005505570A (en) * | 2001-09-19 | 2005-02-24 | アルタナ ファルマ アクチエンゲゼルシャフト | Combination drug of PDE inhibitor and leukotriene receptor antagonist |
| US7144896B2 (en) | 2002-03-18 | 2006-12-05 | Merck Frosst Canada Ltd. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| ZA200507321B (en) * | 2003-03-05 | 2007-03-28 | Celgene Corp | Diphenylethylene compounds and uses thereof |
| EP1732900A4 (en) * | 2004-03-25 | 2007-12-12 | Synta Pharmaceuticals Corp | Acrylonitrile derivatives for inflammation and immune-related uses |
| AU2006248200A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| RS53461B (en) | 2006-07-05 | 2014-12-31 | Takeda Gmbh | COMBINATION OF HMG-COA REDUCTASE INHIBITOR OR SIMVASTATIN WITH PHOSPHODIESTERASE 4 INHIBITOR AS A ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES |
| WO2008006050A2 (en) * | 2006-07-07 | 2008-01-10 | Govek Steven P | Bicyclic heteroaryl inhibitors of pde4 |
| CA2664421A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Hmg coa reductase mediated modulation of neurogenesis |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| CN107260736A (en) | 2010-02-12 | 2017-10-20 | 株式会社ＡｓｋＡｔ | The 5 HT4 receptor stimulating agents for treating dementia |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
| JP2020532551A (en) * | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Vinyl heterocycle as a Rho-related coiled coil kinase (ROCK) inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| JPH11209350A (en) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | Nitrogen-containing heterocyclic derivative and medicine containing the same |
-
2000
- 2000-12-19 MY MYPI20005965A patent/MY134008A/en unknown
- 2000-12-20 WO PCT/CA2000/001559 patent/WO2001046151A1/en not_active Ceased
- 2000-12-20 EA EA200200702A patent/EA004747B1/en not_active IP Right Cessation
- 2000-12-20 IL IL15011400A patent/IL150114A0/en unknown
- 2000-12-20 HU HU0203896A patent/HUP0203896A3/en unknown
- 2000-12-20 PL PL00355752A patent/PL355752A1/en not_active IP Right Cessation
- 2000-12-20 JP JP2001547062A patent/JP3782011B2/en not_active Expired - Fee Related
- 2000-12-20 EE EEP200200342A patent/EE200200342A/en unknown
- 2000-12-20 EP EP00986937A patent/EP1244628A1/en not_active Withdrawn
- 2000-12-20 CA CA002393749A patent/CA2393749C/en not_active Expired - Fee Related
- 2000-12-20 UA UA2002076108A patent/UA74815C2/en unknown
- 2000-12-20 NZ NZ520258A patent/NZ520258A/en unknown
- 2000-12-20 DZ DZ003244A patent/DZ3244A1/en active
- 2000-12-20 HR HR20020545A patent/HRP20020545A2/en not_active Application Discontinuation
- 2000-12-20 AU AU23362/01A patent/AU778531B2/en not_active Ceased
- 2000-12-20 YU YU47102A patent/YU47102A/en unknown
- 2000-12-20 SK SK897-2002A patent/SK8972002A3/en not_active Application Discontinuation
- 2000-12-20 CO CO00096650A patent/CO5261613A1/en not_active Application Discontinuation
- 2000-12-20 GE GE4903A patent/GEP20053626B/en unknown
- 2000-12-20 BR BR0016651-0A patent/BR0016651A/en not_active IP Right Cessation
- 2000-12-20 KR KR1020027008079A patent/KR20020082839A/en not_active Ceased
- 2000-12-20 CZ CZ20022171A patent/CZ20022171A3/en unknown
- 2000-12-20 MX MXPA02006329A patent/MXPA02006329A/en not_active Application Discontinuation
- 2000-12-20 CN CNB00818951XA patent/CN1221534C/en not_active Expired - Fee Related
- 2000-12-21 TW TW089127506A patent/TWI280240B/en not_active IP Right Cessation
- 2000-12-21 AR ARP000106867A patent/AR029214A1/en not_active Application Discontinuation
- 2000-12-22 PE PE2000001396A patent/PE20010989A1/en not_active Application Discontinuation
-
2002
- 2002-06-11 IS IS6413A patent/IS6413A/en unknown
- 2002-06-18 ZA ZA200204862A patent/ZA200204862B/en unknown
- 2002-06-19 BG BG106840A patent/BG65403B1/en unknown
- 2002-06-21 NO NO20023013A patent/NO20023013L/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010989A1 (en) | 8-ARYLQUINOLINES SUBSTITUTED INHIBITORS OF 4-PHOSPHODIESTERASE | |
| EP0862560B1 (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
| PE20071025A1 (en) | TRISUSTITUTED AMINE COMPOUND | |
| PE20011115A1 (en) | TRI-ARIL-SUBSTITUTED ETHANS, PDE4 INHIBITORS | |
| HRP20080226T3 (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| PE20050991A1 (en) | BENZENE SULFONAMIDE DERIVATIVES | |
| MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| YU8703A (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| RU2003136097A (en) | Phenylpyridinecarbonylpiperazine derivatives | |
| AR059249A1 (en) | AMIS TRISUSTITUDED COMPOUND | |
| PE20130325A1 (en) | DERIVATIVES OF PIPERIDINE, PIPERAZINE OR TETRAHYDROPYRIDYL AS ANTAGONISTS OF TRPV1 | |
| UY32314A (en) | DERIVATIVES OF 4-PHENYL-PYRIDINE | |
| ATE463483T1 (en) | 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS | |
| RU2006137272A (en) | 2-Phenylpropionic Acid Derivatives and Their Pharmaceutical Compositions | |
| AR054021A1 (en) | CYCLOPENTAPIRIDINE AND TETRAHYDROQUINOLINE DERIVATIVES | |
| PE20060243A1 (en) | DERIVATIVES OF 4-AMINO INSUSTITUTED-5- (4-UREA-PHENYL) -PYRROLOTRIAZINE | |
| HUP0103987A2 (en) | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates | |
| PE20060298A1 (en) | BENZHIMIDAZOLONE CARBOXYL ACID DERIVATIVES | |
| PE20060121A1 (en) | BICYCLE AMIDES COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M3 | |
| PE20091243A1 (en) | FUSED HETEROCYCLIC COMPOUND | |
| IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| PE20011008A1 (en) | PYRIMIDINE DERIVATIVES AS CYCLOOXYGENASE 2 INHIBITORS | |
| NO20071112L (en) | New heterocyclic carboxylic acid derivatives | |
| EA200300619A1 (en) | SEROTONINERGIC MEANS | |
| YU67601A (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |